CompletedNot Applicable

MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis

Germany138 participantsStarted 2011-06

Plain-language summary

Desmopressin in treatment of nocturnal enuresis (bedwetting).

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency * The patients and their parents have been informed about the study and have given their written consent for participation. Exclusion Criteria: * The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated

What they're measuring

Assessment of patient and parent satisfaction

Timeframe: 3 months

Trial details

NCT IDNCT01368913

SponsorFerring Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-03

View on ClinicalTrials.gov More Nocturnal Enuresis trials